Skip to main content
FDA approves BMS' combo for colorectal cancer indication

The FDA approved Bristol-Myers Squibb's Opdivo, or nivolumab, 3 mg/kg, in combination with low-dose Yervoy, or ipilimumab, 1 mg/kg, as a treatment for patients ages 12 years and up who have certain types of metastatic colorectal cancer that has progressed after treatment with a fluoropyrimidine, oxaliplatin and irinotecan chemotherapy combination.

Full Story: